“Market Cap $7.12 B As of May 2014
At a Glance
- Industry: Pharmaceuticals
- Founded: 1998
- Country: China
- CEO: Li Zhiming
- Employees: 45,415
- Sales: $27.15 B
- Headquarters: Shanghai
#903 Global 2000
- #345 in Sales
- #1495 in Profit
- #1174 in Assets
- #1459 in Market value
Sinopharm Group Co., Ltd. is a distributor of pharmaceutical and healthcare products and a value added supply chain service provider in the People’s Republic of China. The company operates its business through the following segments: Pharmaceutical Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment provides distribution, logistics and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers and other suppliers. The Retail Pharmacy segment handles the day-to-day operation of medicine chain stores. The Other Business segment is engaged in the production and sale of pharmaceutical products, chemical reagents and laboratory supplies. The company was founded on January 8, 2003 and is headquartered in Shanghai, China.“
“SINOPHARM GROUP CO.LTD
Established in January 2003 and listed on the HK Stock Exchange (Stock code: 01099. HK) on September 23, 2009, SINOPHARM GROUP CO.LTD is the largest key member enterprise in the China National Pharmaceutical Group. In the 10 years since its establishment, the SINOPHARM Group has developed into the largest distributor of pharmaceutical and healthcare products and a leading supply chain service provider in the PRC. It embraces and operates the widest range of pharmaceutical product distribution and delivery networks. It has formed an integrated industrial chain consisting of pharmaceutical distribution, logistics and delivery, retail chains, pharmaceutical manufacturing, chemical reagents, medical devices, healthcare industry products and other related industry coordinated industry components.
Since 2005 SINOPHARM Group has consecutively posted the top sales numbers among China’s commercial pharmaceutical enterprises, and continued to have sales of over RMB 100 billion in the past few years. Its market capitalization ranked fourth worldwide in the pharmaceutical distribution industry. It has established partnerships with the world’s leading pharmaceutical companies such as Pfizer, MSD, Bayer, IPSEN, SANKYO, Baxter, etc. SINOPHARM Group has more than 300 wholly owned and controlled subsidiaries (including two domestic listed companies – Sinopharm shares and Shenzhen Accord Pharmaceutical Co., Ltd). Its distribution net covers 180 cities in 31 provinces. 11 regional DCs (Distribution Centers) are located in major cities in the PRC – Beijing, Shanghai, Tianjin, Guangzhou, Shenyang, Changsha, Taiyuan, Wuhan, Nanning, Yangzhou and Shijiazhuang. New DCs are under construction in Urumqi, Zhenzhou, Chengdu, Shijiazhuang and other cities.
In addition to its nationwide distribution network, Sinopharm Group is built on China National Pharmaceutical Group’s powerful pharmaceutical R & D platform and owns 9 industrial pharmaceutical companies. Among these companies is Shenzhen Zhijun Pharmaceutical Co., Ltd., which produces antibiotics, anticancer drugs, cardiovascular drugs, medication, and various health care products. In terms of retail pharmacies, the Guoda Drugstore, which belongs to the SINOPHARM Group, is the top pharmaceutical retail operator in China’s pharmaceutical in terms of sales volume. As one of only 3 licensed nationwide anesthetic distributors in China, the Group now accounts for the vast majority of the market share in the industry.
The Sinopharm Chemical Reagent Co., Ltd which belongs to the Group, is the largest chemical reagent enterprise in China, with a number of well-known independent imported and exported, such as Wokai, SCRC, Hushi, Jingshi, Shenbo.
The Sinopharm Group Medical Devices Co., Ltd. is a professional medical device company providing integrated services including sales agencies, distribution and franchise.
The Sinopharm Group is the national medical reserve unit designated to undertake the emergency supply work in the case of major national disasters, epidemics and accidents. The Group also actively participates in various social charities, has created a core corporate concept – “love life, care health”, and earnestly strives to fulfill its social responsibilities. It has won several awards from central departments and the social organizations. In 2009 the Group earned the world’s first international ethical standards SA8000 certification.
The Sinopharm Group is committed to becoming an internationally competitive pharmaceutical and healthcare service provider. Currently, in light of globalizing trends, the Group is further optimizing industrial resources, transforming from traditional to modern distribution services, from simple drug distribution to a modern integrated healthcare service provider, and accelerating its transition from a pharmaceutical product distributor into a health industry service provider. The Group actively exchanges and seeks cooperation with top global enterprises in the pharmaceutical industry, deepens and expands pragmatic cooperation in the healthcare fields, and identifies areas to enrich cooperation content. In all this, it seeks to further enhance the level of cooperation, complementary advantages, and mutually beneficial win-win situations.”
*Information from Forbes.com and Sinopharmholding.com
**Video published on YouTube by “Why Invest In“